Information Provided By: 
Fly News Breaks for April 21, 2017
AGN
Apr 21, 2017 | 05:52 EDT
Citi analyst Liav Abraham removed Allergan from her firm's U.S. Focus List citing the rally in the shares since late 2016. The analyst, however, keeps a buy rating on Allergan and upped her price target for the stock to $270 from $245. Evidence of execution on key pipeline assets is likely required for further share upside, Abraham tells investors in a research note.
News For AGN From the Last 2 Days
There are no results for your query AGN
